Drug, bio-affecting and body treating compositions inventions 04/07

20070092440 - Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial: The present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that... Agent: Millen, White, Zelano & Branigan, P.C.

20070092442 - F-18-fluorinated phosphonium cation imaging agents and methods of synthesis: The present disclosure provides mitochondrial imaging probes, particularly imaging probes capable of imaging changes in mitochondrial membrane potential and conditions associated with mitochondrial dysfunction.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070092441 - Fluoridation method: A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent.... Agent: Ge Healthcare, Inc.

20070092443 - Antibodies that recognize hyperproliferative cells and methods of making and using same: The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.... Agent: Wilson Sonsini Goodrich & Rosati

20070092444 - Inhibition of inward sodium currents in cancer: Described is a constitutive inward Na+ currents found in a variety of human cancers. The constitutive inward Na+ current plays a role in increased cellular proliferation, cellular migration and volume regulation. The inward current is mediated, at least in part, by AISC-containing Na+ channels. In addition, an inhibitor of the... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070092445 - Assessing ovarian reserve: Methods for assessing the ovarian reserve of a female subject may include (a) testing the concentration of follicle stimulating hormone (FSH) in urine samples obtained from the subject, the samples being obtained on at least two different days during a first menstrual cycle in the subject; (b) testing the concentration... Agent: Foley Hoag, LLP Patent Group, (w/isa)

20070092447 - Contrast agent for combined modality imaging and methods and systems thereof: A combined modality imaging system includes a first imaging device of a first modality and a second imaging device of a second modality that is different from the first modality is provided. The first and the second imaging devices are both adapted to interact with a contrast agent. The contrast... Agent: General Electric Company Global Research

20070092446 - Patient selection method for assisting weight loss: A method is provided for identifying a patient as being suitable for implantation of a weight-loss assist device. The method includes identifying the patient as being generally suitable for the implantation and subsequently, measuring a value associated with the patient. Responsively to determining that the value is beyond a threshold... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070092448 - Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same: The present invention provides methods which use induction phenomenon of production of interleukin 18 (IL-18) from keratinocyte (KC), and their usages. The methods are preferably applicable for understanding of pathogenic mechanisms of atopic dermatitis (AD) and AD-like symptoms, and for development of therapeutic drugs for AD and AD-like symptoms. For... Agent: Edwards & Angell, LLP

20070092449 - Methods for direct visualization of active synapses: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070092450 - Tissue-specific exogenous optical agents: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Wood, Herron & Evans, LLP

20070092451 - Time indicating containers for dental compositions: A system for storing a dental composition having a given shelf-life. The storage system includes a container (e.g., a syringe) and activatable time sensitive marking means disposed on or within the container. Upon activation of the time sensitive marking means, the system begins to indicate time lapsed since activation. The... Agent: Rick D. Nydegger Workman Nydegger

20070092452 - Methods for fabrication, uses, compositions of inhalable spherical particles: Inhalable spherical particles that contain an active agent having unexpectedly good bioavailability when compared to the expected bioavailability are disclosed. Inhalable spherical particles, particles of the agent that contain an amount of a cation such as zinc provide for further improvement in bioavailability.... Agent: Baxter Healthcare Corporation

20070092453 - Novel crystalline forms of tiotropium bromide: The invention relates to a new crystalline forms of tiotropium bromide, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070092455 - Aqueous slurries useful for cleaning teeth and methods related thereto: Novel aqueous slurries capable of removing calculus, plaque or stains, adherent to tooth surfaces of a warm-blooded animal, when used in methods that are self-practicable by an individual human or practicable by an individual human on another warm-blooded animal, combine finely-divided charcoal; water; and alcohol, ammonia or hydrogen peroxide to... Agent: Seed Intellectual Property Law Group PLLC

20070092454 - Oral composition containing morin: The present invention relates to an oral composition useful to reduce inflammatory processes. More specifically, the invention relates to a composition consisting essentially of an anti-oxidative effective amount of morin and a water-humectant phase, and to a composition comprising an anti-oxidative effective amount of morin, one or more anti-bacterial agents... Agent: Colgate-palmolive Company

20070092456 - Protectant of periodontal membranes: e

20070092457 - Compositions comprising polymeric emulsifiers and methods of using the same: Provided are oil-in-water sunscreen compositions comprising inorganic sunscreens and polymeric emulsifiers that are substantially free of hydrophobic modification, and methods of using the same.... Agent: Philip S. Johnson Johnson & Johnson

20070092458 - Compositions comprising polymeric emulsifiers and methods of using the same: Provided are oil-in-water sunscreen compositions comprising inorganic sunscreens and polymeric emulsifiers that are substantially free of hydrophobic modification, and methods of using the same.... Agent: Philip S. Johnson Johnson & Johnson

20070092459 - Cosmetic preparation with 1,2-alkanediol and triazines: A cosmetic preparation which comprises one or more 1,2-alkanediols and one or more UV light-protection filters from the group of triazine derivatives. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20070092460 - Silylated compounds as precursors for self-tanning compositions: The use of silylated compounds as precursors of skin self-tanning substances in self-tanning compositions is described.... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070092461 - Novel hydroxy acid complexes for antiaging and skin renovation: This invention relates to certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including Molybdenum, complexed concurrently with an amino acid, or an equivalent of an amino acid, and a hydroxy acid in a novel spirocyclic... Agent: Shyam K. Gupta Bioderm Research

20070092462 - Cosmetic compositions: A cosmetic composition comprising in a preblend; or in a the resting state prior to application to a keratinous surface, at least one peptide, at least one collagen containing compound, at least one penetration enhancer, at least one mucopolysaccharide, and at least one proteoglycan; wherein said ingredients are operable to... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070092463 - Semi (soft)-solid antiperspirant compositions: Stable semi-solid anhydrous antiperspirant compositions comprising an antiperspirant powder, a volatile silicone and non-volatile materials, a primary gellant material comprising Glyceryl monostearate, secondary gellants, oil absorbents, and coupling agents. The resultant products exhibit minimal syneresis with any dispensing package and exhibiting dry feeling when applied to skin.... Agent: The Halvorson Law Firm

20070092464 - Betadine neutralizer: A new preparation for the removal of iodine stains in clinical or home environments is disclosed as an aqueous solution of a metabisulfite in the preferred range of 0.01 to 0.04 percent by weight, metabisulfite to water. The preferred metabisulfite for this purpose is sodium metabisulfite. In one embodiment of... Agent: Christopher D. Harrington Suite 350

20070092466 - Compositions and methods for treating hair loss using c16-c20 aromatic tetrahydro prostaglandins: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.... Agent: Michael Best & Friedrich, LLP

20070092465 - Methods for enhancing the morphology, tone, texture and/or appearance of skin or hair using a meadowlactone: The present invention provides inexpensive, safe and reliable methods for improving the morphology, tone, texture and/or appearance of the skin and/or hair of a mammal, preferably without using one or more surfactants (or other chemicals) that can strip away, or otherwise remove, one or more protective lipids from the skin... Agent: Keith D. Parr Lord, Bissell & Brook LLP

20070092467 - Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers: e

20070092470 - Liquid, peg-free, cold-processable oil-in-water emulsifiers: The invention provides liquid, cold-processable oil-in-water emulsifier systems comprising a liquid, PEG-free emulsifier base consisting of A) one or more polyol partial esters, Ba) one or more acid partial esters carrying neutralizable acid functions, or Bb) one or more acid partial esters carrying at least partially neutralized acid functions, and... Agent: Leopold Presser Scully, Scott, Murphy & Presser

20070092469 - Topically applied glucosamine sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while phosphatidylcholine is re: A topical skin rejuvenation preparation to relieve wrinkles, increase the skin's natural production of hyaluronic acid, reverse the lack of suppleness, hydrate from within, erase spider veins, reduce varicose veins, lighten aging dark blotches (“liver spots”/Lentigos, Senile Lentigines), decrease acne, and reduce under eye puffiness includes Glucosamine (2-amino-2-deoxy-alpha-D-glucose), a hexosamine... Agent: Eric Jacobs

20070092471 - Composition for the oxidative treatment of hair or skin fixative compostion and method for permanent deformation of hair: Cosmetic composition for the oxidative treatment of hair or skin, prepared by mixing of at least two components, in which dehydroascorbic acid or a dehydroascorbic acid salt or a dehydroascorbic acid derivative is generated from ascorbic acid, ascorbic acid derivative and ascorbic acid salt prior to application by an enzyme... Agent: Striker, Striker, & Stenby

20070092472 - Skin care composition for accelerated production of collagen proteins and method of fabricating same: A liquid solution for topical application to the skin of an animal consists of solutes and a solvent, where the solutes include ascorbate, tropocollagen, copper, and zinc glutonate.... Agent: Marger Johnson & Mccollom, P.C.

20070092473 - Cosmetic composition containing a statistical polymer with a linear main chain of ethylenic nature: l

20070092474 - Carnitine salt, preliposome which contains it and dermocosmetic formula for topical use based upon said carnitine salt: The carnitine salt consisting of carnitine hydroxy citrate of formula (I) of natural origin for treating skin blemishes linked to physiological disorders ascribable to cellulite and anomalous adiposity connected to this. With respect to conventional solutions, the new carnitine salt of the invention proves to be particularly efficient and, above... Agent: The Firm Of Karl F Ross

20070092476 - Compounds and use to reduce the formation of malodour: Malodour formation reducing compounds alpha-N-(3-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, alpha-N-(2-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, and alpha-N-(2,4-Dimethyl-4-phenylbutanoxycarbonyl)-L-glutamine, and their salts, compositions comprising such compounds, including cosmetic products, personal care products, and deodorant products, and methods forming such products and their use. The compounds are useful to reduce the formation of human malodour resulting from bacterial degradation of compounds naturally... Agent: Curatolo Sidoti Co., Lpa

20070092475 - Methods for enhancing the morphology, tone, texture and/or appearance of skin using a meadowestolide: The present invention provides inexpensive, safe and reliable methods for improving the morphology, tone, texture and/or appearance of the skin of a mammal, preferably without using one or more surfactants (or other chemicals) that can strip away, or otherwise remove, one or more protective lipids of the skin. These methods... Agent: Keith D. Parr Lord, Bissell & Brook LLP

20070092477 - Cleaning compositions: Improved treatment blocks useful in the treatment of lavatory appliances, particularly toilets are provided. The improved treatment blocks are solid block compositions which comprise at least one detersive surfactant, a diester constituent, and one or more further optional constituents, including bleach constituents. The improved treatment blocks provide improved processing and... Agent: Norris, Mclaughlin & Marcus

20070092478 - Emulsion comprising 1,2-alkanediols and polar oil components: An emulsion comprising (a) more than about 40% by weight, based on the total weight of the lipid phase of the emulsion, of one or more polar and/or moderately polar lipids which exhibit an interfacial tension towards water of less than about 30 mN/m and (b) one or more 1,2-alkanediols... Agent: Greenblum & Bernstein, P.L.C

20070092468 - Cosmetic compositions: A cosmetic composition having improved transfer resistance comprising: a) from about 0.1-60% by weight of trimethylated silica, b) from about 0.1-60% by weight of a volatile solvent having a viscosity of 0.5 to 100 centipoise at 25° C., c) 0.1-60% by weight of a nonvolatile oil having a viscosity of... Agent: Julie Blackburn, Esq. Revlon Consumer Products Corporation, Law Dept.

20070092479 - Odor mitigation compositions, devices, and methods: Methods, devices, and corresponding compositions for generally simultaneously camouflaging and suppressing odors by applying at least one odor absorbing agent, optionally a plurality of differently colored odor absorbing agents, directly to a user and/or to garments and/or accessories used in hunting and/or observing and/or photographing wild animals. The odor absorbing... Agent: Wilhelm Law Service, S.c.

20070092480 - Inducible release vehicles: This invention relates to inducible release vehicle comprised of crosslinked carbohydrates or proteins and an active ingredient. The release is induced by an external stimulus, e.g. an enzyme such as amylase. Such a vehicle can particularly be used in applications for preventing microbial decay or combating microbial infections. Other uses... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070092482 - Conjugates of a g-csf moiety and a polymer: Conjugates of a G-CSF moiety and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient.... Agent: Nektar Therapeutics

20070092483 - Surgical adhesive compostion and process for enhanced tissue closure and healing: A surgical tissue adhesive composition contains at least one 1,1-disubstituted electron-deficient olefin macromer. The adhesive composition of the invention has improved biocompatibility as well as controlled biodegradation characteristics and bioactivity. Adhesive co-monomer compositions contain at least one macromer with a pendant oligomer, polymer, or peptide chain as an acrylic ester... Agent: Dergosits & Noah LLP

20070092481 - Thickened cyanoacrylate compositions: The present invention relates to thickened cyanoacrylate compositions, such as those in gel or non-flowable forms. More particularly, the present invention relates to non-flowable cyanoacrylate compositions which can be packaged in a convenient pocket-sized applicator dispenser for use in spreading the cyanoacrylate compositions onto substrates.... Agent: Loctite Corporation

20070092485 - Cytokine zalpha11 ligand: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070092486 - Glycolated and glycosylated poultry derived therapeutic proteins: Compositions containing a glycosylated therapeutic amino acid sequence obtained from a transgenic avian wherein the therapeutic amino acid sequence is a glycoprotein and includes a covalently bonded glycol polymer.... Agent: Avigenics, Inc.

20070092484 - Mcp-1 splice variants and methods of using same: Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition... Agent: Staas & Halsey LLP

20070092488 - Methods of treating idiopathic pulmonary fibrosis: The present invention provides methods of treating idiopathic pulmonary fibrosis (IPF); methods of increasing survival time in an individual with IPF; and methods of reducing risk of death in an individual with IPF. The methods generally involve administering a therapeutically effective amount of IFN-γ to an individual with IPF.... Agent: Foley & Lardner LLP

20070092487 - Stabilized liquid protein formulations in pharmaceutical containers: A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON and contains a HSA-free Interferon-β formulation having the following composition: 30 to 100 μg/ml of interferon-β, an isotonicity agent, 0.1 to... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070092490 - High efficiency sin vector: The present application discloses viral vector that includes the following elements: (1) a promoter in U3 region of MSV 5′LTR; (2) repeating unit of MSV 5′LTR; (3) U5 region of MSV 5′LTR; (4) packaging signal; (5) a promoter; (6) internal ribosome entry site (IRES); (7) defective MLV 3′ LTR; (8)... Agent: Jhk Law

20070092489 - Use of receptor sequences for immobilizing gene vectors on surfaces: The present invention relates to compositions and methods of immobilizing a viral vector to an implantable medical device, for example a vascular stent. Specifically, a composition for delivery of a therapeutic agent is provided which includes: a gene transfer vector, a surface and a modified protein, wherein the gene transfer... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070092499 - Method for changing genetic properties of eukaryotic organism: The invention provides a method for changing the genetic properties of an eukaryotic organism by suppression of expression of a target gene. Proposed method can be used in gene-therapy in medicine, agriculture, or industrial biotechnology. Genetic properties of an eukaryotic organism are changed by gene-specific silencing of a selected gene... Agent: Buchanan, Ingersoll & Rooney PC

20070092500 - Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α).... Agent: Altera Law Group, LLC

20070092498 - Methods of diagnosing, prognosing and treating breast cancer: The protein pRb2/p130 represses expression of the ER-α gene. Blocking pRb2/p130 expression or altering ER-α gene methylation to alter pRb2/p130 complex binding allows transcriptional activity of the ER-α gene to be restored. Detecting and regulating the methylation state of the ER-α gene, optionally together with detecting and regulating pRb2/p130 multimolecular... Agent: Ip Group Of Dla Piper US LLP

20070092491 - Novel strain of bacillus as a bioinoculant: The present invention relates to the selection and development of superior strain of Bacillus spp for improving plant growth and health by inhibiting pathogenic fungi... Agent: Sughrue Mion, PLLC

20070092494 - Composition for wound healing using lyophilized skin or skin-derived collagen: A wound healing composition for repairing a wound in a human or animal subject, comprising a first skin tissue material and a carrier comprising collagen derived from a second skin tissue material. Methods of making the wound healing composition and methods of augmenting a wound site with the composition are... Agent: Harness, Dickey & Pierce, P.L.C

20070092497 - Cytotherapeutics, cytotherapeutic units and methods for treatments using them: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are... Agent: Jones Day

20070092493 - Living cell sheet: A novel method, using a thermoreversible MC/PBS/Collagen hydrogel coated on the TCPS dish, for harvesting a living cell sheet with ECM. The coated hydrogel system is reusable and can be used for culturing a multi-layer cell sheet. The obtained living cell sheets may be used for tissue reconstructions.... Agent: Hosheng Tu

20070092496 - Method of delivering cells to the skin: The present invention is a method of forming egressing hair shafts comprising making a wound in the skin and placing hair follicle progenitor cells on the wound, wherein an egressing hair shaft is formed from the hair follicle progenitor cells. The present invention is also a method of forming new... Agent: Michael Best & Friedrich, LLP

20070092495 - Methods for regulating differentiation of neural cells and uses thereof: The present invention provides methods for promoting or suppressing differentiation of neural stem/progenitor cells, for producing differentiated neural cells, and for isolating/purifying differentiated neural cells. Also provided are differentiated neural cells, cell populations and transgenic animals comprising same, and uses of same. The present invention further provides methods for treating... Agent: Baker & Botts L.L.P.

20070092492 - Three-dimentional tissue structure: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing... Agent: Snell & Wilmer L.L.P. (main)

20070092501 - Compositions and methods relating to reduction of symptoms of autism: Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin... Agent: Graybeal, Jackson, Haley LLP

20070092502 - Method of treating glaucoma: The present invention provides a method of treating glaucoma or preventing glaucoma in a person at risk of developing glaucoma, by applying to the eye of said person, an effective amount of an antibacterial agent having activity against the Heliocobacter Pylori bacteria to thereby eradicate, inhibit and/or control said bacteria.... Agent: Allergan, Inc.

20070092503 - Human alkaline sphingomyelinase and use thereof: An isolated human alkaline sphingomyelinase (Alk-Smase) or a variant thereof is capable of hydrolysing sphingomyelin. Methods are provided for isolating human Alk-Smase and for preparing human recombinant Alk-Smase. Further methods are provided for the use of the enzyme for the treatment of colon cancer.... Agent: Albihns Stockholm Ab

20070092507 - Anti-fcrn antibodies for treatment of auto/allo immune conditions: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as... Agent: Hodgson Russ LLP

20070092505 - Production of humanized antibodies in transgenic animals: This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present... Agent: Heller Ehrman LLP

20070092504 - Use of agents that modulate the interaction between pd-1 and its ligands in the downmodulation of immune responses: Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response.... Agent: Lahive & Cockfield, LLP

20070092506 - Use of rapamycin and agents that inhibit b7 activity in immunomodulation: The invention provides methods for downmodulating an immune response comprising contacting immune cells from a subject with at least one agent that binds to at least one B7 molecule in combination with a Rapamycin compound.... Agent: Foley Hoag, LLP Patent Group, (w/wys)

20070092508 - Detoxification depot for alzheimer's disease: The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve... Agent: Mccormick, Paulding & Huber LLP

20070092509 - Method for ex-vivo separation of apoptotic chromatin fragments from blood or plasma for prevention and treatment of diverse human diseases: A method of prevention/treatment of pathological consequences of DNA damage triggered by incorporation of circulating apoptotic chromatin fragments into healthy cells of individuals/patients in need therefore, said method comprising ex vivo or extra corporeal treatment of blood/plasma for removal of circulating chromatin fragments released from apoptotic cells which apoptotic chromatin... Agent: Merchant & Gould PC

20070092510 - Cns chloride modulation and uses thereof: Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such... Agent: Ladas & Parry LLP

20070092513 - Erbb4 antagonists: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing... Agent: Heller Ehrman LLP

20070092511 - Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells: The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070092514 - Novel secreted immunomodulatory proteins and uses thereof: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding... Agent: Millennium Pharmaceuticals, Inc.

20070092512 - Preventing bacterial or viral infectivity and composition containing infection preventing additive: A nitric oxide synthesis inhibitor or nitric oxide scavenger is administered to prevent development of infection, to prevent development of a cancer where overstimulation of a receptor contributes to the cancer development, and to prevent loss of beta agonist responsivity and as a treatment in combination with a receptor blocker.... Agent: Bacon & Thomas, PLLC

20070092516 - Antibody preparation: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants... Agent: Nixon & Vanderhye, PC

20070092515 - Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin: Methods to treat secondary injury resulting from spinal cord injury using polypeptide compositions that specifically bind to CD11d are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070092518 - Anti-tnfalpha antibodies and methods of use: Novel TNFα antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNFα-related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070092517 - Truncated memapsin 2 compositions and treatments: The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step... Agent: Townsend And Townsend And Crew, LLP

20070092521 - Antibody-based therapeutics with enhanced adcc activity: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070092520 - Humanized anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.... Agent: Genentech, Inc.

20070092522 - Method and composition for reconforming multi-epitopic antigens to initiate an immune response: The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070092519 - Method for diagnosing chronic myeloid leukemia: Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment... Agent: Townsend And Townsend And Crew, LLP

20070092523 - Combination therapy of respiratory diseases using antibodies: Therapeutically effective anti-microbial compositions, useful especially against respiratory diseases caused or mediated by viruses, bacteria, and other respiratory parasites are disclosed, wherein said compositions comprise at least one neutralizing antibody, including high affinity antibodies, and an additional anti-infectious agent, such as an antiviral agent, for example, ribavirin, amantadine, rimantadine, or... Agent: Johnathan Klein-evans

20070092524 - Method for the treatment and prophylaxis of avian influenza infection: This invention relates to methods and compositions for treatment and prevention of Avian Influenza. Specifically, the invention relates to the use of immunoglobulins obtained from a subject immune to Avian Influenza in the preparation and use of pharmaceutical preparations for the treatment of Avian Influenza.... Agent: Pearl Cohen Zedek Latzer, LLP

20070092525 - Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates... Agent: Fulbright & Jaworski L.L.P.

20070092526 - Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use: Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine formulations are disclosed which are useful in prophylactic or therapeutic vaccine and/or gene therapy-based applications. These adjuvants comprise a block copolymer and a cationic surfactant component. The inclusion of a cationic surfactant results in an increased percentage of polynucleotide that is physically... Agent: Merck And Co., Inc

20070092530 - Antibodies as t cell receptor mimics, methods of production and uses thereof: The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such... Agent: Dunlap, Codding & Rogers P.C.

20070092532 - Arthritis vaccines and methods: Vaccine compositions for preventing the onset or induction of arthritis in a subject susceptible to developing arthritis, comprising an arthritic protective peptide comprising the amino acid sequence of SEQ ID NO: 1. In various embodiments, the anti-arthritic peptide is admixed with an adjuvant in a pharmaceutically acceptable carrier. Methods include... Agent: Harness, Dickey & Pierce, P.L.C

20070092529 - Compositions and methods for diagnosing and treating cancers: Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070092531 - Compositions for immunotherapy and uses thereof: The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070092527 - Proton-sensing g-protein coupled receptors and dna sequences thereof: This invention relates to the newly identified utility of certain G protein-coupled receptors (GPCRs), in particular to OGR1, GPR4 and TDAG8 (TDAG8 is also named GPR65) polypeptides, and polynucleotides encoding such GPCR polypeptides, to their use in diagnosis and to methods of identifying compounds that are agonists or antagonists to... Agent: Novartis Corporate Intellectual Property

20070092528 - Superantigen fusion protein for anti-cancer therapy and methods for the production thereof: The present invention provides a fusion protein, comprising: a) a ligand that stimulates cancer cell growth and corresponds to receptors overexpressed by cancer cells, or a screened peptide that is affinitive to or antagonist to cancer cell receptors, or a peptide that directly interacts with cancer cell surface; b) a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070092533 - Method of preventing t cell-mediated responses by the use of the major histocompatibility complex class ii analog protein (map protein) from staphylococcus aureus: A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an... Agent: Stites & Harbison PLLC

20070092535 - Delivery of drugs to mucosal surfaces: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070092534 - Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070092536 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Intellectual Property Dept.

20070092537 - Compositions and methods for the treatment of canine influenza virus disease: Compositions, including vaccine compositions, and methods for treating, preventing or ameliorating canine influenza virus (CIV) disease by utilizing one or more canine influenza virus (CIV) or equine influenza virus (EIV) strain or immunogens thereof are set forth herein. Also set forth are challenge models useful in assessing the efficacy of... Agent: Wyeth Patent Law Group

20070092538 - Immunogenic reagents from west nile virus: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive... Agent: Novartis Vaccines And Diagnostics Inc.

20070092540 - Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives... Agent: Bozicevic, Field & Francis LLP

20070092539 - Method of preparing an aqueous meloxicam solution and aqueous solution thus produced: A method of solubilizing a selective inhibitor active agent of cyclo-oxigenase-2 (COX-2), such as meloxicam, and a method of preparing an ophthalmic solution from the solubilized meloxicam for the treatment of distinct ocular affections are described. The invention also refers to an aqueous ophthalmic solution resulting from the method, said... Agent: Knobbe Martens Olson & Bear LLP

20070092542 - Cosmetic o/w emulsion comprising 1,2-hexanediol: A cosmetic oil-in-water emulsion which comprises 1,2-hexanediol and a method of preparing same.... Agent: Greenblum & Bernstein, P.L.C

20070092541 - Direct contact quench crystallization process and cosmetic products produced thereby: A process for making a solid cosmetic composition comprising the steps of: forming at least one hot process stream comprising a solvent and a gellant dissolved therein, the hot process stream having a first temperature; forming at least one cold process stream comprising a cosmetic active having a second temperature... Agent: The Procter & Gamble Company Intellectual Property Division

20070092545 - Aerosol coolant spray for killing and removing ticks: A composition of an aerosol coolant spray for killing and removing ticks from mammal skin, to be dispensed from a pressurized a pressurized aerosol spray cannister. The aerosol coolant spray composition includes a liquid coolant material for freezing the essential oil and the cooled essential oil for immobilizing and killing... Agent: Ezra Sutton P.A.

20070092547 - Method for treating/controlling/killing fungi and bacteria: This present teaching describes how to treat substrates with novel compositions in order to limit fungi, dermatophytes, yeasts, and bacteria thereon.... Agent: Sonnenschein Nath & Rosenthal LLP

20070092544 - Natural insect repellant: Disclosed is a pesticide method and composition utilizing a mixture of cedar and cinnamon oils as active pesticide agents in an inert carrier. The composition may also utilize a surfactant. Exemplary embodiments disclosed herein may include up to 8.5% by volume of cedar oil, up to 8.5% cinnamon oil, lemon... Agent: Cislo & Thomas, LLP

20070092543 - Tablets having an emulsified polymer matrix for the controlled emission of gas, and production process: Tablets capable of producing a gas in a controlled manner for its preferred use in apparatuses intended for the administration of medicaments or serums, such that the gas exerts the control of the rate of release of the serum or medicament to the patient. The tablets comprise an emulsified polymer... Agent: Vedder Price Kaufman & Kammholz

20070092546 - Thiamin based insect repellant: The present invention provides a topical application of thiamin to human skin or mammalian coats to provide effective insect repellency. Any commercially available thiamin compounds such as thiamin hydrochloride or thiamin mononitrate can be combined with a pharmaceutically or cosmetically acceptable carrier for preparing a composition for topical application. This... Agent: LatimerIPLaw, LLP

20070092548 - Semiochemical reservoir to attract subterranean termites tunneling in soil: The present invention relates generally to polymer devices impregnated with semichemical attractants for termites. The materials for delivering the semiochemicals are preferably cellulose-free. Devices of the subject invention are placed in soil and provide a slow-release and permeation of the semiochemicals into the adjacent soil so that termites tunneling in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070092549 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least... Agent: Buchanan, Ingersoll & Rooney PC

20070092550 - Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants: This invention discloses methods to attach and grow a monolayer of cultured human corneal endothelial cells onto the endothelial side of the stroma synthesized from biopolymer to generate a more bio-equivalent artificial cornea. The approaches will include the use of attachment and growth promoting agents such as fibronectin, laminin, RGDS,... Agent: Jacobson Holman PLLC

20070092551 - Therapeutic agent: A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized... Agent: Birch Stewart Kolasch & Birch

20070092552 - Chewable lozenge cold remedy composition and method for making same: A chewable lozenge for the treatment of cold symptoms having a zinc formulation which includes both zinc gluconate and zinc actetate.... Agent: Cynthia L Pillote Snell & Wilmer

20070092553 - Compositions and methods of making rapidly dissolving lonically masked formulations: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug... Agent: Chalker Flores, LLP

20070092554 - Sexual dysfunction compounds: The present invention provides for a sexual dysfunction compound comprising a rapid-onset pharmaceutical composition that further comprises cocoa powder. The invention also provides for a process for manufacturing the composition, and use of the composition in sexual dysfunction therapy.... Agent: Fulbright & Jaworski, LLP

20070092555 - Thermotolerant phytase for animal feed: The invention provides a synthetic phytase polynucleotide which is optimized for expression in plants and which encodes at thermotolerant phytase, as well as isolated thermotolerant phytase enzyme. Also provided are feed or food products comprising a thermotolerant phytase, and transgenic plants which express the thermotolerant phytase. Further provided are methods... Agent: Syngenta Biotechnology, Inc. Patent Department

20070092556 - Anti-microbial material and method of making the same: A material to be used for furniture, drapery, wall covering and other similar objects in hospitals and the healthcare industry is formed of a skin with an inorganic anti-microbial compound attached to a backing. The skin includes a film impregnated with said compound and one or more layers of polyurethane... Agent: Gottlieb Rackman & Reisman PC

20070092557 - Method of preparing biodegradable dual pore polymer scaffolds for tissue engineering: There is provided a method of preparing biodegradable dual pore polymer scaffolds, comprising the steps of: maintaining a polymer solution containing a biodegradable polymer, an effervescent mixture of carbonate and organic acid, and solvent at a temperature range of −196° C. to ambient temperature so as to evaporate the solvent... Agent: Jones Day

20070092558 - Methods of preparing targeted immunoliposomes: Methods of preparing targeting ligand bound avidin-lipid vesicles for use in preparing a targeted, therapeutic liposome composition are disclosed. Each vesicle comprises an avidin molecule coupled to the polymer-conjugated biotin which retains multiple free site biotin-binding sites such that the vesicle may be used to further couple a biotinylated-targeting ligand.... Agent: Philip S. Johnson Johnson & Johnson

20070092560 - Lipophilic vehicle-based dual controlled release matrix system: A lipophilic vehicle-based dual controlled-release matrix, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a suspension, which allows for easier formulation of low dose compounds and/or compounds which are moisture sensitive. The matrix includes two rate controlling barriers for the... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070092559 - Liquid dosage forms having enteric properties of delayed and then sustained release: Pharmaceutical preparations and methods that contain enteric polymers formulated in liquid dosage forms. The preparations and methods provide enteric properties of delayed and then sustained release, without the need for expensive tableting or coating processes.... Agent: Eastman Chemical Company

20070092563 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070092564 - Orally distintegrating formulation and process for preparing the same: An orally disintegrating formulation and its preparation are provided. The orally disintegrating formulation comprises an effective amount of a pharmaceutically active ingredient and a matrix, wherein the matrix contains an amino acid and pullulan. The orally disintegrating formulation can disintegrate rapidly in oral cavity and be taken without aid of... Agent: Darby & Darby P.C.

20070092562 - Product and process for increasing compactibility of carbohydrates: The present invention includes a method for preparing a highly compactible carbohydrate product, and the product itself. In one embodiment, a composition according to the present invention is a quick-dissolving composition that includes polyols.... Agent: Morgan, Lewis & Bockius LLP

20070092561 - Water-soluble aspirin composition: Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which... Agent: Cermak & Kenealy LLP

20070092565 - Gastric retention drug delivery system: A gastric retention drug delivery system (i.e. a controlled release drug dosage form) formulated so as to promote retention of the dosage form in the upper gastrointestinal tract and in particular the stomach.... Agent: Bcf LLP 25th Floor

20070092566 - Oral sustained-release tablet: An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. (Solving means) An oral sustained-release tablet comprises a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070092567 - Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.... Agent: Merchant & Gould PC

20070092569 - Extended release formulation of levetiracetam: The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible... Agent: Blank Rome LLP

20070092568 - Galantamine compositions: The present invention relates to controlled release compositions of galantamine, processes to prepare the compositions, their in-vitro release profiles and method of use and method of treatment using the said compositions.... Agent: Dr. Reddy's Laboratories, Inc.

20070092570 - Drug delivery device: Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for disposing on a target tissue and a well having an opening to the internal surface. An... Agent: Alcon

20070092571 - Non-irritating formulation and method for the intradermal delivery of substances: This invention describes a composition of matter to facilitate intra-dermal delivery of a great variety of active substances, especially including high molecular weight cosmicuticals. Also disclosed is a method of forming the composition of matter and applying topically to patients, especially using a cream or patch. The active substance is... Agent: Robert J. Van Der Wall Gables One Tower

20070092572 - Bone cement compositions and the like comprising an rnaiii-inhibiting peptide: RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Avoiding sustained chemotherapy reduces the risk of inducing antibiotic resistance. Accordingly, RIP can be used with antibiotics that otherwise... Agent: Merchant & Gould PC

20070092573 - Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist: The present invention is a new stable extended release drug composition particularly suitable for use as a beta-adrenoreceptor antagonist agent. The present invention is specifically a drug composition comprising a pharmaceutical, a methacrylic acid copolymer and a matrix forming agent, and a method for manufacturing same. When applied to highly... Agent: Peacock Myers, P.C.

20070092576 - Compositions containing opioid antagonists: Compositions containing opioid antagonists are disclosed, particularly alvimopan and its active metabolite in solid dosage forms, where the drug is uniformly distributed, achieves the desired bioavailability, and is stable. Methods of preparing and using the compositions containing opioid antagonists are also disclosed. The results are achieved by a combination of... Agent: Woodcock Washburn LLP

20070092575 - Compositions for administering rnaiii-inhibiting peptides: Compositions comprising RIP are advantageously formulated in compositions allowing sustained release and protection from degradation, and improved therapeutic efficacy. To that end, RIP compositions may be delivered to the skin or mucosal membranes as a salve or the like. Alternatively or additionally, RIP compositions may be administered in polymeric nanoparticle... Agent: Merchant & Gould PC

20070092574 - Controlled released compositions: The compositions disclosed herein are for use as controlled release therapeutics for the treatment of a wide variety of diseases. In particular, the compositions provide water soluble bioactive agents, organic ions and polymers where the bioactive agent is efficiently released over time with minimal degradation products. The resulting controlled release... Agent: Jennifer M Mccallum, Ph D, Esq The Mccallum Law Firm, LLC

20070092577 - Dietary calcium for reducing the production of reactive oxygen species: The subject application provides a method of identifying or screening compounds or compositions suitable for reducing the production of reactive oxygen species (ROS) comprising: a) feeding (or orally administering) compositions comprising dietary material containing dietary calcium (or dietary calcium) to at least one subject; b) measuring intracellular concentrations of calcium... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070092578 - Skin rejuvinating supplement: A skin rejuvenating supplement composition for treating age spots, darkening of the skin, dry skin, calcium amino acid deficiencies, osteoporosis and eye site deficiencies. The composition contains 100 to 1,500 mg of pearl powder, 0.6 to 50 μkg Vitamin D, 1.5 to 20.0 mg of astaxanthin and 20 to 750... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070092579 - Medical products and parenteral formulations: A medical product and parenteral formulation are provided. The parenteral formulation is preferably for fluid restricted patients such as pediatric patients and can include amino acids, lipids, carbohydrates and electrolytes. The parenteral formulation can be housed in a multi-chamber container for separately storing a amino acid component, a lipid component... Agent: Baxter Healthcare Corporation

20070092580 - Dual-phase cement precursor systems for bone repair: Disclosed are dual-phase cement precursor systems and related methods and kits. The cement precursor systems are composed of a first and second discrete phases, at least one of which is aqueous. When combined, the cement precursor phases form a cement that is suitable as a bone graft material for bone... Agent: Banner & Witcoff, Ltd.

20070092581 - Hydrogen cyanamide pesticide formulations: Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect.... Agent: Townsend And Townsend And Crew, LLP

20070092582 - Methods of preserving ophthalmic solutions and preserved ophthalmic solutions: A preservative system for aqueous ophthalmic solutions is provided, where the preservative system comprises a hydrogen peroxide source, at least one hydrogen peroxide stabilizer and an alkali earth metal salt.... Agent: Novartis Corporate Intellectual Property

20070092583 - Cold remedy composition comprising zinc salts: A composition to treat symptoms of cold and/or prevent the onset of cold symptoms and methods of forming and using the composition are disclosed. The composition is formulated to maintain one or more active ingredients in association with an oral membrane for an extended period of time. The invention further... Agent: Snell & Wilmer L.L.P. (main)

20070092584 - Combinations of chromium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070092585 - Cancer chemotherapy compositions comprising pi3k pathways modulators and triptolide: The present invention provides compositions and methods for inhibiting growth of and/or killing cancer cells. The compositions include: an inhibitor of the PI3K signal transduction pathway, and additional agents, such as Triptolide.... Agent: Mandel & Adriano

20070092586 - Compositions and methods for the administration psychotropic drugs which modulate body weight: Embodiments of the invention describe compositions and methods for the administration of fast disintegrating atypical antipsychotics, metabolites of atypical antipsychotics, and antidepressants which reduce weight in patients previously taking conventional formulation of atypical antipsychotics and antidepressants. In a preferred embodiment said fast dissolving atypical antipsychotic is FAZACLO. In another preferred... Agent: Knobbe Martens Olson & Bear LLP

20070092587 - Extract from plant of japanese parsley family and process for producing the same: The present invention provides an extract obtainable by extracting a plant belonging to Umbelliferae, or a processed product thereof, with a water-containing alcohol; a process for preparing the extract; a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response and/or... Agent: Birch Stewart Kolasch & Birch

20070092588 - Soy milk made from germinated soy beans: Soymilk is provided which can prevent or alleviate menopausal disorders, and is highly safe with no risk of side effects even with long-term intake thereof. This soymilk is made from germinated soybeans, and is used for alleviating or preventing the vasomotor disorder-like symptoms and psychoneuropathic disorder-like symptoms associated with menopausal... Agent: David B. Ritchie Thelen Reid & Priest, LLP

20070092589 - Veterinary pharmaceutical compositions for gastric ulcers: y

20070086944 - Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.... Agent: Kramer Levin Naftalis & Frankel LLP

20070086943 - Epha2 agonistic monoclonal antibodies and methods of use thereof: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2... Agent: Jones Day

20070086942 - Methods and compositions for generating bioactive assemblies of increased complexity and uses: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD)... Agent: Faegre & Benson LLP Patent Docketing

20070086945 - Preparations for diagnosis of pancreatic exocrine function: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070086946 - Assay: The present invention relates, in general, to a method of assaying an immune response induced by an immunogen, and, more particularly, to a method of assaying a immunogen for its ability to induce a desired immune response, wherein the assay is effected in an autoimmune animal.... Agent: Nixon & Vanderhye, PC

20070086947 - System and method for selecting a pillow and mattress: A method is provided for selecting a pillow and mattress based upon an empirical measurement of an individual's pillow selection criteria, mattress selection criteria and sleep characteristics. A system incorporating the principles of the method are also disclosed.... Agent: Thompson Coburn, LLP

20070086948 - Tissue metabolic stress monitoring: Various pathophysiological states are determined by evaluating the rate of 17O-containing water production oxygen using proton MRI. The method can be used to identify viable but threatened myocardium, injured by viable muscle, penumbra tissue in a stroke patient, and the like.... Agent: Dickstein Shapiro LLP

20070086950 - Gat2 transporters expressed in blood brain barrier cells: GAT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the GAT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in... Agent: Townsend And Townsend And Crew, LLP

20070086949 - Method of bioimaging using nanocrystals of fluorescent dyes: This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic organic fluorescent dyes as stable dispersions in an aqueous system. The dispersions can be prepared without stabilizers such as surfactants and the like. The aqueous dispersions of the nanocrystals or the polymer doped nanocrystals can be used for bioimaging.... Agent: Hodgson Russ LLP

20070086951 - Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments: i

20070086953 - Medicinal aerosol formulation products with improved chemical stability: The present invention relates to a medicinal aerosol formulation product with improved chemical stability. The product is a pressurized metered dose inhaler including an aerosol canister equipped with a metering valve provided with sealing rings and/or gaskets made of a vulcanisate of an elastomeric composition of a butyl rubber, a... Agent: Holme Roberts & Owen, LLP

20070086954 - Method and apparatus for treatment of respiratory infections by nitric oxide inhalation: Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas, in... Agent: Sidley Austin LLP Suite 4000

20070086952 - Rapid acting and prolonged acting inhalable insulin preparations: It has been discovered that by combining a chelator, such as ethylenediaminetetraacetic acid, with an acidifier, such as citric acid, the insulin is absorbed much more rapidly than in the absence of the chelator and acidifier, with a commercially available rapid, intermediate or long lasting insulin such as glargine, one... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070086957 - Combination of medicaments for the treatment of respiratory diseases: R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070086955 - Form of administration for controlling primary headaches: The invention relates to a nasally applied, film-shaped, bioadhesive pharmaceutical form of administration containing at least one agent-containing layer that is based on crosslinked hydrophilic polymers comprising up to 60 percent by weight of Lidocaine, the percentage being in relation to the total quantity of crosslinked hydrophilic polymers. Also disclosed... Agent: Frommer Lawrence & Haug

20070086958 - Formation of medically useful gels comprising microporous particles and methods of use: Compositions and methods use the gel-forming properties of microporous particles to create useful formulations combining two free-flowing materials to produce a hydrogel mass. The free-flowing materials preferably provide dry microporous particles (preferably as an aerosol) that may contain additional agents, and a second composition of a fluid material which is... Agent: Mark A. Litman & Associates, P.A.

20070086956 - Method for accelerating the rate of mucociliary clearance: The instant invention provides for a composition and method for using Kunitz-type serine protease inhibitors, e.g., aprotinin or bikunin, for stimulating the rate of mucociliary clearance of mucus and sputum in lung airways of subjects afflicted with mucociliary dysfunctions such as cystic fibrosis.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070086959 - Use of a compositionally gradient copolymer in an aerosol device comprising two compartments, and aerosol device comprising said copolymer and a compressed gas: The invention relates to an aerosol device with two compartments, which contains the following: (a) in a first compartment, a hair treatment composition comprising, in a cosmetically-acceptable aqueous medium, at least one compositionally-graded copolymer comprising at least two different monomers and having a mass polydispersity index (Ip) of less than... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070086960 - Systems and methods for enhancing the appearance of teeth: Effective, non-invasive and non-destructive systems and methods provide an appearance of increased whiteness and/or brightness of the teeth, thereby enhancing the appearance of the teeth. One or more residual colors or dyes are applied to the surface of a tooth in order to complete the color spectrum of the tooth... Agent: Kirton And Mcconkie

20070086961 - Tooth whitening substances: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division

20070086962 - Stable sunscreen composition: A stable sunscreen composition comprising: (i) an organic UV-A sunscreen; (ii) an organic UV-B sunscreen; and (iii) cosmetically acceptable vehicle wherein said UV-A sunscreen and UV-B sunscreen are kept isolated from each other by encapsulating one of said sunscreens in solid lipid encapsulate, the solid lipid encapsulate comprising a lipid.... Agent: Unilever Intellectual Property Group

20070086963 - Apparatus to apply a hair care preparation: A method for coloring hair with a hair care formulation that is mixed prior to use is provided. The method includes mixing together the components of the hair care formulation as the formulation is dispensed from a plastic applicator having at least one storage compartment for each component and a... Agent: Bereskin And Parr

20070086965 - Chromonic nanoparticles containing bioactive compounds: A chromonic nanoparticle mixture prepared by combining (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material; and non-covalently crosslinking the resulting chromonic nanoparticles with a polyvalent cation salt.... Agent: 3m Innovative Properties Company

20070086964 - Method for making chromonic nanoparticles: A chrmonic nanoparticle mixture prepared by combining (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material; and non-covalently crosslinking the resulting chromonic nanoparticles with a polyvalent cation salt.... Agent: 3m Innovative Properties Company

20070086966 - Cosmetic product containing mineral water for remineralising and rejuvenating the skin: The invention relates to a cosmetic composition that can be used to remineralise human skin and to counteract the effects of ageing on the latter. According to the invention, said composition contains 0.5-3% water of volcanic origin containing 0.01-0.05 mg/l Fe, 100-300 mg/l K, 1,000-2,000 mg/l Na, 80-200 mg/l Mg,... Agent: Akerman Senterfitt

20070086967 - Treatment of psoriasis with rosiglitazone: Disclosed is a method of treatment of psoriasis which comprises administering to a patient in need thereof by the oral route a pharmaceutical composition comprising rosiglitazone, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, wherein the method comprises administering 2 to 8 mg rosiglitazone... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070086968 - Hydrolysis resistant organomodified disiloxane surfactants: s

20070086969 - Miracle hair treatment: A composition for the treatment of hair. The composition consists essentially of mayonnaise being present in the composition in a concentration of between about 55 and 64 percent by weight. Olive oil is present in the composition in a concentration of between about 12 and 15 percent by weight, carrot... Agent: James Ray & Associates

20070086970 - Hair cleansing compositions: A hair cleansing composition comprises the following ingredients (A) to (C): (A) a dicarboxylic acid or hydroxydicarboxylic acid, or a salt thereof, (B) an organic solvent, and (C) an anionic surfactant having a sulfate group; and has a pH of from 1 to 4 when diluted 20-fold by weight with... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070086971 - Acidic cleaning compositions: A composition comprising a mixing product of: (i) a first acid having a pKa of less than 3, in an amount by weight of 1-10%, (ii) a second acid having a pKa of greater than 3, in an amount by weight of 1-10%, (iii) a nonionic surfactant in an amount... Agent: Colgate-palmolive Company

20070086972 - Hair growth compositions and methods for treating hair loss or related conditions: The present invention relates to hair growth compositions as well as to methods for treating hair loss or related conditions.... Agent: Jacob Birnbaum

20070086974 - Cetirizine compositions: Stable and palatable taste masked pharmaceutical compositions of substituted benzhydrylpiperazines and processes for preparing them.... Agent: Dr. Reddy's Laboratories, Inc.

20070086976 - Acyclic n-halamines in antibacterial materials: The present invention provides biocidal polymers having N-halamine technology incorporated therein, which are useful for a wide range of applications. The microbiocidal polymer can be a homopolymer, a co-polymer or a grafted polymer. In certain aspects, the present invention provides polymers from acrylic amine-monomers such as acrylamide, which monomers readily... Agent: Townsend And Townsend And Crew, LLP

20070086977 - Method of treating dermatological conditions: A method of treating a patient having a dermatological condition which comprises administering to the patient a composition comprising a complex characterized as having a maximum water solubility of about 5 wt. % and further characterized as being a complex that is formed by a metathesis reaction between a bioactive... Agent: Law Offices Of Jack Matalon

20070086975 - Polymeric micellar complexes and drug delivery vehicles thereof: Disclosed are complexes of an amphiphilic copolymer, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of the copolymer.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070086973 - Drug delivery systems for photodynamic therapy: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more... Agent: Morrison & Foerster LLP

20070086978 -